Lessons from Wolfram Syndrome: Initiation of DDAVP Therapy Causes Renal Salt Wasting Due to Elevated ANP/BNP Levels, Rescued by Fludrocortisone Treatment

• Published in: Indian journal of pediatrics 2021-06, Vol.88 (6), p.582-585
• Main Authors: Kleanthous, Kleanthis, Maratou, Eirini, Spyropoulou, Dora, Dermitzaki, Eleni, Papadimitriou, Anastasios, Zoupanos, George, Moutsatsou, Paraskevi, Mastorakos, George, Urano, Fumihiko, Papadimitriou, Dimitrios T.
• Format: Article
• Language: English
• Subjects: Atrial Natriuretic Factor; Child; Clinical Brief; Deamino Arginine Vasopressin - therapeutic use; Female; Fludrocortisone - therapeutic use; Gynecology; Humans; Hyponatremia - chemically induced; Hyponatremia - drug therapy; Medicine; Medicine & Public Health; Pediatrics; Wolfram Syndrome; Young Adult
• ISSN: 0019-5456; 0973-7693
• DOI: 10.1007/s12098-020-03538-y

Initiation of desmopressin acetate (DDAVP) for untreated diabetes insipidus (DI) in Wolfram syndrome (WS) causes abrupt volume expansion resulting in particularly high secretion of Atrial Natriuretic Peptide (ANP) and/or Brain Natriuretic Peptide (BNP), which in turn blocks all stimulators of zona glomerulosa steroidogenesis, resulting in secondary mineralocorticoid deficiency and acute hyponatremia, causing renal salt wasting (RSW). Two sisters, a 19-y-old girl (A) and a 7-y-old girl (B) with WS, presented with severe polyuria-polydipsia due to never treated DI. Both had neurogenic bladder and “B” had severe hydronephrosis secondary to untreated grade III bilateral vesicoureteral reflux. They initiated therapy with oral melt DDAVP which resulted in RSW. ANP was found ×50 and BNP ×2–4 fold elevated. Fludrocortisone 100–200 × 2 μg/d controlled natriuresis and restored electrolytes to normal within 48 h. Fludrocortisone treatment rescues otherwise potentially life-threatening hyponatremia due to RSW and the secondary mineralocorticoid deficiency driven by elevated ANP and/or BNP, caused by sudden volume expansion following DDAVP initiation.